BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
Phase 3
Withdrawn
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Bayer
- Registration Number
- NCT00313976
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT00313248
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries
Phase 3
Completed
- Conditions
- Renal Artery Stenosis
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 116
- Registration Number
- NCT00310557
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
Phase 2
Completed
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 73
- Registration Number
- NCT00310544
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Phase 3
Completed
- Conditions
- Osteopenia
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT00310531
Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00310596
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches
Phase 3
Completed
- Conditions
- Cardiovascular Abnormalities
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 123
- Registration Number
- NCT00310609
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 126
- Registration Number
- NCT00309075
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Phase 3
Completed
- Conditions
- Metrorrhagia
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 231
- Registration Number
- NCT00307801
- Locations
- 🇦🇺
Private Practice Dr. Ian Fraser, Ashfield, New South Wales, Australia
🇨🇿Gynekologicko-poradnicka ambulance Dr. Hlavackova, Pisek, Czech Republic
🇩🇪emovis GmbH, Berlin, Germany
Identification of Hepatic Lesions
Phase 3
Completed
- Conditions
- Hepatic Neoplasms
- Interventions
- Procedure: Resovist (BAY86-4884, SH U 555 A)
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 218
- Registration Number
- NCT00307866
© Copyright 2025. All Rights Reserved by MedPath